Semaglutide

GLP-1 (glucagon-like peptide-1) receptor agonist

Quick Answer

A synthetic peptide that mimics the human hormone GLP-1, which is released naturally after eating and helps regulate blood sugar and appetite.

Why People Are Interested

It's the compound most responsible for a broader cultural conversation about GLP-1 medications — headlines about "the weight-loss shot" nearly always trace back to this molecule. It's also one of the few peptides in this library with large-scale, FDA-approved evidence behind it, which is an unusual combination: major cultural moment and genuinely strong evidence.

What People Hope It May Do

People discuss semaglutide (under its approved brand names) for meaningful weight loss and blood-sugar control. There's also growing curiosity about whether its cardiovascular, liver, or neurological signals — still being studied — might extend its role further. Those additional areas are active research questions, not additional approvals. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)

Potential / Research Areas

How It May Work

Binds to and activates GLP-1 receptors, which increases insulin secretion in response to meals, slows gastric emptying, and acts on appetite-regulating centers in the brain to reduce hunger.

What Human Research Shows

Extensive — semaglutide has been evaluated in multiple large, randomized, placebo-controlled Phase 3 trials (the STEP and SUSTAIN trial programs) involving thousands of participants, which supported its FDA approvals. This is a substantially higher evidence tier than most compounds in this database.

What Preclinical Research Shows

Preceded human trials with standard preclinical pharmacology and toxicology studies typical of an FDA drug-approval pathway.

What People Report

What Experts Are Saying

Curated commentary specific to Semaglutide is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving Semaglutide, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

Commonly reported effects in clinical trials include gastrointestinal symptoms (nausea, vomiting, diarrhea). Prescribing information includes warnings relevant to thyroid tumors observed in animal studies and other contraindications. This is general information, not individualized medical guidance — full prescribing information and a licensed provider's judgment govern actual use.

Regulatory Status

FDA-approved under three brand names for specific indications: Ozempic (type 2 diabetes management, injectable), Wegovy (chronic weight management in adults/adolescents with obesity or overweight plus a weight-related condition, injectable), and Rybelsus (type 2 diabetes management, oral). Approval is indication- and formulation-specific — "semaglutide is FDA-approved" should never be stated as a blanket claim without naming the specific approved product and use.

What We Still Don't Know

Long-term (multi-year) outcomes after stopping treatment, the durability of weight loss without continued use, and the full picture of its neurological/anti-inflammatory signals are all still being studied.

Limitations of Evidence

Most large trials are manufacturer-sponsored (Novo Nordisk), which doesn't invalidate the results but is worth disclosing. Long-term (multi-year) data on weight regain after stopping treatment is still an active research area.

Keep Researching

• Search ClinicalTrials.gov for Semaglutide
• Expert & Creator Library
• This Week in Peptides
• Understanding Your Bloodwork
• Related peptides:
  • Tirzepatide
  • Retatrutide